Serological assessment of PRO-C16 (type XVI collagen formation) reflects intestinal fibrostenotic strictures in patients with crohn’s disease

Serological assessment of PRO-C16 (type XVI collagen formation) reflects intestinal fibrostenotic strictures in patients with crohn’s disease

Abstract Background Fibrostenotic stricturing disease affects 30–50% of patients with Crohn’s disease (CD), leading to intestinal resection. Currently, there exists a great medical need to identify biomarkers related to fibrostenotic strictures for optimized patient management. Thus, we investigated...

Full description

Saved in:
Bibliographic Details
Main Authors: Joachim H. Mortensen, M. Lindholm, L. Langholm, P. Giuffrida, D. Ruane, T. Manon-Jensen, G. Mazza, F. Caprioli, L. Pastorelli, A-C. Bay-Jensen, M. Pinzani, M. A. Karsdal, A. Di Sabatino
Format: Article
Language:English
Published: BMC 2025-08-01
Series:BMC Gastroenterology
Subjects:
Crohn's disease
Stenosis
Intestinal fibrosis
Biomarkers
Collagen
Type XVI collagen
Online Access:https://doi.org/10.1186/s12876-025-04146-w
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Fibrostenotic stricturing disease affects 30–50% of patients with Crohn’s disease (CD), leading to intestinal resection. Currently, there exists a great medical need to identify biomarkers related to fibrostenotic strictures for optimized patient management. Thus, we investigated PRO-C16 as a biomarker for intestinal fibrosis in patients with CD. Methods Human serum from two independent cohorts of CD patients (cohort 1: n = 44, cohort 2: n = 52), healthy subjects (n = 37), and serum from a chronic rat dextran sodium sulfate (DSS) colitis model were included. The Montreal classification for CD disease behavior was applied for patient phenotyping. Results PRO-C16 was elevated in patients with CD compared to healthy donors (P < 0.001), and in CD patients with fibrostenotic strictures in both cohorts. Furthermore, PRO-C16 was able to separate CD patients with strictures(B2) from CD patients without strictures (B1 and B3) (Cohort 1 [P < 0.01, AUC:0.75], and Cohort 2 [P < 0.05, AUC:0.71). In the chronic DSS rat colitis model, PRO-C16 was elevated after the second and fourth cycles of DSS, reflecting collagen deposition in that model. Conclusion The biomarker PRO-C16 was associated with a stricturing disease phenotype, indicating that PRO-C16 may be a potential marker of intestinal fibrosis in CD, with the potential to aid in the clinical development of novel stromal-immune therapeutic agents.
ISSN:1471-230X

Similar Items